Greenwich Rx, a compounding pharmacy based in Tomball, Texas, on 20 November 2026 announced a nationwide consumer-level recall of compounded sterile injectables, including versions of semaglutide and tirzepatide, citing a potential lack of sterility assurance that surfaced after a US Food and Drug Administration (FDA) inspection.

The company's announcement, posted by the FDA, said the recall covers specific lots still within their beyond-use dates, including products Greenwich Rx compounded for another pharmacy, Clove Rx. The affected medicines were dispensed nationwide between 10 August and 21 September 2026.

Which products are being recalled?

The recall spans 31 injectable products and 261 lots, according to the lot list published by Greenwich Rx. They include compounded semaglutide combined with vitamin B12, glycine or methylcobalamin; compounded tirzepatide combined with B12, glycine, L-carnitine or methylcobalamin; and a range of peptide and wellness injections such as BPC-157, TB-500, GHK-Cu, NAD+, glutathione, sermorelin, tesamorelin, thymosin alpha-1, PT-141, Lipo-B and Lipo-C.

Patients are asked to compare the product name, lot number and beyond-use date on their medication label with the published list.

How serious is the risk?

The company said using a drug meant to be sterile that is not sterile could cause serious infections, which may be life threatening. It also said it has not found evidence of contamination in the recalled products and is acting as a precaution, and that it had received no reports of adverse events linked to this recall as of the announcement.

The concerns arose after the FDA inspected the pharmacy and Greenwich Rx evaluated the affected products, the announcement said. Greenwich Rx describes itself as a 503A compounding pharmacy, and the recall is being carried out with the FDA's knowledge.

What should patients do?

  • Stop using any recalled product immediately and discard it, following the FDA's guidance on safe disposal of unused medicines.
  • Customers of Clove Rx should check the list even if they have not received a direct notice; Greenwich Rx is notifying its own affected customers by mail.
  • Questions can go to the recall handler Sedgwick on 888-243-5547 (8 am to 5 pm US Eastern Time, Monday to Friday).
  • Anyone who has had problems that may be related to the products should contact a doctor and can report reactions to the FDA's MedWatch programme.

Second recall in two months

This is the pharmacy's second recall this autumn. On 1 October 2026, Greenwich Rx recalled 12 lots of compounded glutathione injection over potential elevated endotoxin levels. In that notice it reported two cases of patients who needed emergency department care after intravenous administration of a glutathione product that was not formulated for intravenous use.

Why compounded weight-loss injections are under scrutiny

Compounded GLP-1 drugs are not FDA-approved. Telehealth companies began selling lower-cost compounded copies of obesity medicines when demand outstripped supply, and Eli Lilly and Novo Nordisk say the quality and safety of such versions cannot be guaranteed, BioPharma Dive reported in October, when another compounder, Apothecary Pharma, recalled 22 lots of compounded tirzepatide. The FDA classified that recall as Class II. Brand-name products from the drugmakers are not part of the Greenwich Rx recall, which covers only the pharmacy's own compounded preparations.

The recall applies to products dispensed in the United States. MapMyTimes recently reported on another US drug recall, one lot of Breckenridge propranolol capsules over possible metal contamination, and on Union Minister Jitendra Singh's caution on weight-loss drugs in India.

Photo source · Epolk, CC BY-SA 4.0